Bifidobacterium longum BB536 for Infant Colic
Verdict: Insufficient Evidence
Across 6 PubMed studies, the evidence for Bifidobacterium longum BB536 in Infant Colic grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.
U ⚫ U Unverified Insufficient Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
65%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.434
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Probiotics to prevent infantile colic
Finding: No significant effect on preventing colic onset (RR 0.46, 95% CI 0.18-1.19), but daily crying time was reduced (MD -32.57 min/day, 95% CI -55.60 to -9.54), driven by L. reuteri (MD -44.26 min/day); GRADE certainty LOW.
View on PubMed Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis
Finding: Individual-participant-data MA of 4 double-blind RCTs: L. reuteri DSM17938 cut crying/fussing by -25.4 min/day at day 21 (95% CI -47.3 to -3.5); treatment success in BREASTFED infants only (IRR 1.7, 95% CI 1.4-2.2, NNT 2.6), no benefit in formula-fed.
View on PubMed Probiotics for infantile colic: Is there evidence beyond doubt? A meta-analysis and systematic review
Finding: Probiotics overall reduced crying by ~51 min/day (p=0.001), strongest in exclusively breastfed infants (-74.28 min/day, p=0.0003); L. reuteri DSM17938 -64.66 min/day (p=0.03); evidence for formula-fed and caesarean-born infants was limited.
View on PubMed Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial
Finding: B. longum CECT7894 + P. pentosaceus CECT8330 (1x10^9 CFU/day) shortened crying vs placebo at day 21 (14 vs 40 min/day, p<0.001), with day-21 responder rate 89.5% vs 64.3%; strain is B. longum CECT7894/KABP042, NOT BB536.
View on PubMed Comparative efficacy of probiotic mixture Bifidobacterium longum KABP042 plus Pediococcus pentosaceus KABP041 vs. Limosilactobacillus reuteri DSM17938 in the management of infant colic: a randomized clinical trial
Finding: B. longum KABP042 + P. pentosaceus KABP041 (10^9 CFU/day) beat L. reuteri DSM17938 (10^8 CFU/day): day-14 responders 84.6% vs 59.3% (p=0.004), day-21 crying 29 vs 67 min/day (p=0.011); single-blind; strain is KABP042, NOT BB536.
View on PubMed Probiotics in Term Infants: Clinical Impact of Infant-Type Bifidobacteria: A Systematic Review and Meta-analyses
Finding: Across 25 RCTs the primary benefit was eczema prevention (RR 0.78, 95% CI 0.68-0.90); for colic, only 1 of 7 studies (Giglione) showed reduced crying (MD -35.10 min/day, 95% CI -55.41 to -13.51), rest inconclusive; review EXPLICITLY EXCLUDED B. longum BB536 as not infant-type.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.) source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve… source↗
L4d TW TFDA / 衛福部
Neutral
健康食品查驗登記審查採雙軌制，第一軌為「個案審查」，第二軌為「規格標準審查」，通過審查的產品會給予健康食品(小綠人)標章，第一軌的產品上標有「衛部健食字第A00000號」，第二軌的產品標有「衛部健食規字第000000號」。目前健康食品可以宣稱的保健功效項目共有13項，包括調節血脂、胃腸功能改善、護肝、免疫調節、骨質保健、不易形成體脂肪、抗疲勞、輔助調整過敏體質、調節血糖、延緩衰老、牙齒保健、促進鐵吸收、輔助調節血壓。 source↗
L5b Mayo Clinic
Cautious
Some studies have shown less crying time when babies with colic were treated with a bacterium called Lactobacillus reuteri. However, most experts agree that the study results don't support the use of probiotics to treat colic at this time. The studies have been done with small groups, and results have been mixed. Most Mayo Clinic pediatricians don't recommend the routine use of probiotics in in… source↗
L5e Specialty Society (condition-mapped)
Cautious
Probiotics, gripe water or gas drops may be worth a try, but discuss it with your pediatrician first. source↗